Cargando…

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)

OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease‐modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY‐PDIII is a 36‐month, Phase 3, parallel group, placebo‐controlled study of the efficacy of isradipine 10 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biglan, Kevin M., Oakes, David, Lang, Anthony E., Hauser, Robert A., Hodgeman, Karen, Greco, Brittany, Lowell, Jillian, Rockhill, Rebecca, Shoulson, Ira, Venuto, Charles, Young, Diony, Simuni, Tanya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454402/ https://www.ncbi.nlm.nih.gov/pubmed/28589163 http://dx.doi.org/10.1002/acn3.412

Ejemplares similares

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
por: Venuto, Charles S., et al.
Publicado: (2021)

Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
por: Berk, Sarah, et al.
Publicado: (2017)

Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials
por: Di Luca, Daniel G., et al.
Publicado: (2023)

Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)
por: Schneider, Ruth B., et al.
Publicado: (2020)

Nano-colloidal carrier via polymeric coating for oral delivery of isradipine
por: Kumar, Vikash, et al.
Publicado: (2017)

S53. COMPARISON OF RALOXIFENE AND ISRADIPINE AS AN ADJUNCTIVE TREATMENT IN COGNITIVE DEFICITS OF PATIENTS WITH SCHIZOPHRENIA
por: Vahdani, Bita, et al.
Publicado: (2018)

Development and evaluation of isradipine via rutin-loaded coated solid–lipid nanoparticles
por: Kumar, Vikash, et al.
Publicado: (2018)

Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials
por: Shoulson, Ira, et al.
Publicado: (2022)

Practical Radiosynthesis and Preclinical Neuroimaging of [(11)C]isradipine, a Calcium Channel Antagonist
por: Rotstein, Benjamin H., et al.
Publicado: (2015)

Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling
por: Javidnia, Monica, et al.
Publicado: (2021)

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study
por: Dorsey, Ray, et al.
Publicado: (2011)

Cation Transport in Escherichia coli : III. Potassium fluxes in the steady-state
por: Schultz, Stanley G., et al.
Publicado: (1962)

A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug
por: Copenhaver, Philip F., et al.
Publicado: (2011)

Isradipine therapy in Cacna1d(Ile772Met/+) mice ameliorates primary aldosteronism and neurologic abnormalities
por: Stölting, Gabriel, et al.
Publicado: (2023)

Phenotype–genotype discrepancies in the prospective Huntington at‐risk observational study
por: Shoulson, Ira, et al.
Publicado: (2019)

Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial
por: Kumar, Nihit, et al.
Publicado: (2020)

What Patients Say: Large-Scale Analyses of Replies to the Parkinson’s Disease Patient Report of Problems (PD-PROP)
por: Marras, Connie, et al.
Publicado: (2023)

A molecular approach to treating cognition in schizophrenia by calcium channel blockade: An open-label pilot study of the calcium-channel antagonist isradipine
por: Burdick, Katherine E., et al.
Publicado: (2020)

Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models
por: Luo, Sheng, et al.
Publicado: (2021)

Are type III–IV muscle afferents required for a normal steady-state exercise hyperpnoea in humans?
por: Dempsey, Jerome A, et al.
Publicado: (2014)

Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
por: Wang, Qi-Min, et al.
Publicado: (2017)

Sorption Behaviors of Light Lanthanides(III) (La(III), Ce(III), Pr(III), Nd(III)) and Cr(III) Using Nitrolite
por: Wójcik, Grzegorz
Publicado: (2020)

Antimony Removal from Water by a Chitosan-Iron(III)[ChiFer(III)] Biocomposite
por: Lapo, Byron, et al.
Publicado: (2019)

Taste Cells of the Type III Employ CASR to Maintain Steady Serotonin Exocytosis at Variable Ca(2+) in the Extracellular Medium
por: Cherkashin, Aleksandr P., et al.
Publicado: (2022)

Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases
por: Purks, Jennifer L., et al.
Publicado: (2017)

Number theory III: Diophantine geometry
por: Lang, Serge
Publicado: (1991)

Organorhodium(III)- and Iridium(III)-Substituted 20-Tungstobismuthates(III) and -Antimonates(III), [(MCp*)(2)X(2)W(20)O(70)](10–) (M = Rh(III) and Ir(III); X = Bi(III) and Sb(III))
por: Mougharbel, Ali S., et al.
Publicado: (2021)

Electrochemical oxidation of As(iii) on Pd immobilized Pt surface: kinetics and sensing performance
por: Alam, Md. Mahbubul, et al.
Publicado: (2018)

Catalytic Hydrolysis of Tricresyl Phosphate by Ruthenium (III) Hydroxide and Iron (III) Hydroxide towards Sensing Application
por: Zhou, Lang, et al.
Publicado: (2020)

A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease
por: Larson, Danielle N., et al.
Publicado: (2021)

A New ternary organometallic Pd(ii)/Fe(iii)/Ru(iii) self-assembly monolayer: the essential ensemble synergistic for improving catalytic activity
por: Ren, Ruirui, et al.
Publicado: (2021)

pd-parser: A tool for Matching Photodiode Deflection Events to Time-Stamped Events
por: Rockhill, Alexander P., et al.
Publicado: (2020)

CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON’S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA’S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES
por: McFarthing, Kevin, et al.
Publicado: (2019)

Hexaamminecobalt(III) hexacyanidomanganate(III)
por: Visser, Hendrik G., et al.
Publicado: (2008)

Structural and photophysical studies on ternary Sm(III), Nd(III), Yb(III), Er(III) complexes containing pyridyltriazole ligands
por: Gusev, Alexey N., et al.
Publicado: (2012)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Internal tremor in people with Parkinson’s Disease: Demographic characteristics and comorbid symptoms
por: Chahine, Lana M., et al.
Publicado: (2023)

Magnetic Nature of the Cr(III)–Ln(III) Interactions in [Cr(III) (2)Ln(III) (3)] Clusters with Slow Magnetic Relaxation
por: Zhao, Xiao‐Qing, et al.
Publicado: (2018)

Hydroxo-Bridged Dicopper(II,III) and -(III,III) Complexes: Models for Putative Intermediates in Oxidation Catalysis
por: Halvagar, Mohammad Reza, et al.
Publicado: (2014)

Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
por: Paulsen, J S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_oj0uptjr5c3npdaohouh5h4k5l